Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Transcriptomic deconvolution of blood identifies elevated circulating endothelial signatures (ECS%) that associate with higher 28‑day mortality and worse respiratory trajectories in pediatric respiratory failure and adults hospitalized with
A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2
A multicentre randomized Phase 2a/b trial found inhaled pegylated adrenomedullin (PEG‑ADM) well tolerated in ventilated ARDS patients but without improvement in ventilator‑free survival or a composite clinical utility index; the study was s
A post‑hoc analysis of the RINO trial found rescue NIV for post‑extubation respiratory failure had a 58% failure rate but was associated with lower ICU mortality and no clear increase in hospital mortality when applied with prespecified re‑
Exploring altered cardiopulmonary dynamics and exercise intolerance in adolescents post-sport-related concussion reveals attenuated cardiovascular responses independent of aerobic deconditioning, highlighting autonomic dysregulation as a ke
A 100‑patient CT substudy from the ASPEN program found that brensocatib, especially the 25‑mg dose, reduced mucus plugging and increased healthy parenchyma at 52 weeks, providing preliminary imaging evidence that it may modify disease biolo
Analysis of MASK‑air app data from 2015–2022 found lower self‑reported adherence to ICS+formoterol versus other ICS+LABA combinations, but paradoxically lower short‑acting β2‑agonist (SABA) use and similar symptom control in ICS+formoterol
A pragmatic randomized trial in Kenyan public hospitals demonstrates that adjunctive low-dose glucocorticoid therapy significantly reduces 30-day mortality in adults with community-acquired pneumonia without increasing serious adverse event
A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.
This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.
This study reveals multiple distinct molecular mechanisms, including epithelial and macrophage pathways, that contribute to residual asthma exacerbations in children treated with mepolizumab, highlighting the complexity of airway inflammati
This economic evaluation from the CYCLE randomized trial found no significant cost or quality-adjusted life-year benefit by adding early in-bed cycling to usual physiotherapy for ICU patients on mechanical ventilation, underscoring a need f
A secondary analysis of a cluster-randomized trial found that portable HEPA purifiers modestly reduced viral diversity but did not significantly lower high respiratory viral exposure in elementary school classrooms, suggesting multi-faceted
This study examines how pandemic-related nonpharmaceutical interventions affected immunity development to Streptococcus pyogenes and common respiratory viruses in children aged 0-4 years, offering insights into rising invasive infections.
This article reviews a phase 3 trial analyzing sotatercept’s efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.
This article reviews recent clinical trial data showing sevabertinib’s efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.
This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.
This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.
This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.
Open language-specific specialty feeds and department pages.